261 related articles for article (PubMed ID: 22247743)
1. Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome.
Michail S; Kenche H
Probiotics Antimicrob Proteins; 2011 Mar; 3(1):1-7. PubMed ID: 22247743
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial.
Ankersen DV; Weimers P; Bennedsen M; Haaber AB; Fjordside EL; Beber ME; Lieven C; Saboori S; Vad N; Rannem T; Marker D; Paridaens K; Frahm S; Jensen L; Rosager Hansen M; Burisch J; Munkholm P
J Med Internet Res; 2021 Dec; 23(12):e30291. PubMed ID: 34904950
[TBL] [Abstract][Full Text] [Related]
3. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
[TBL] [Abstract][Full Text] [Related]
4. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Sun YY; Li M; Li YY; Li LX; Zhai WZ; Wang P; Yang XX; Gu X; Song LJ; Li Z; Zuo XL; Li YQ
Sci Rep; 2018 Feb; 8(1):2964. PubMed ID: 29445178
[TBL] [Abstract][Full Text] [Related]
5. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study.
Wong RK; Yang C; Song GH; Wong J; Ho KY
Dig Dis Sci; 2015 Jan; 60(1):186-94. PubMed ID: 25092036
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
Francavilla R; Piccolo M; Francavilla A; Polimeno L; Semeraro F; Cristofori F; Castellaneta S; Barone M; Indrio F; Gobbetti M; De Angelis M
J Clin Gastroenterol; 2019 Mar; 53(3):e117-e125. PubMed ID: 29688915
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
Kim HJ; Camilleri M; McKinzie S; Lempke MB; Burton DD; Thomforde GM; Zinsmeister AR
Aliment Pharmacol Ther; 2003 Apr; 17(7):895-904. PubMed ID: 12656692
[TBL] [Abstract][Full Text] [Related]
8. No distinction in the gut microbiota between diarrhea predominant-irritable bowel syndrome and healthy subjects: matched case-control study in Thailand.
Jandee S; Chuensakul S; Maneerat S
Gut Pathog; 2021 Mar; 13(1):16. PubMed ID: 33658063
[TBL] [Abstract][Full Text] [Related]
9. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kanarek E; Sowińska A; Cukrowska B
Nutrients; 2021 Feb; 13(3):. PubMed ID: 33652763
[TBL] [Abstract][Full Text] [Related]
10. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
Mazzawi T; Hausken T; Hov JR; Valeur J; Sangnes DA; El-Salhy M; Gilja OH; Hatlebakk JG; Lied GA
Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584
[No Abstract] [Full Text] [Related]
11. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis.
Dang X; Xu M; Liu D; Zhou D; Yang W
PLoS One; 2020; 15(3):e0228846. PubMed ID: 32182248
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study.
Mazzawi T; Hausken T; Refsnes PF; Hatlebakk JG; Lied GA
Microorganisms; 2022 Sep; 10(9):. PubMed ID: 36144420
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
Ishaque SM; Khosruzzaman SM; Ahmed DS; Sah MP
BMC Gastroenterol; 2018 May; 18(1):71. PubMed ID: 29801486
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
[TBL] [Abstract][Full Text] [Related]
15. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome.
Hod K; Dekel R; Aviv Cohen N; Sperber A; Ron Y; Boaz M; Berliner S; Maharshak N
Neurogastroenterol Motil; 2018 Dec; 30(12):e13456. PubMed ID: 30136337
[TBL] [Abstract][Full Text] [Related]
16. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome.
Boonma P; Shapiro JM; Hollister EB; Badu S; Wu Q; Weidler EM; Abraham BP; Devaraj S; Luna RA; Versalovic J; Heitkemper MM; Savidge TC; Shulman RJ
Front Pain Res (Lausanne); 2021; 2():691689. PubMed ID: 35295488
[No Abstract] [Full Text] [Related]
17. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Wei W; Wang HF; Zhang Y; Zhang YL; Niu BY; Yao SK
World J Gastroenterol; 2020 Dec; 26(45):7153-7172. PubMed ID: 33362374
[TBL] [Abstract][Full Text] [Related]
18. Protocol for faecal microbiota transplantation in irritable bowel syndrome: the MISCEAT study - a randomised, double-blind cross-over study using mixed microbiota from healthy donors.
Hurych J; Vejmelka J; Hlinakova L; Kramna L; Larionov V; Kulich M; Cinek O; Kohout P
BMJ Open; 2022 Jun; 12(6):e056594. PubMed ID: 35760542
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.
Hod K; Sperber AD; Ron Y; Boaz M; Dickman R; Berliner S; Halpern Z; Maharshak N; Dekel R
Neurogastroenterol Motil; 2017 Jul; 29(7):. PubMed ID: 28271623
[TBL] [Abstract][Full Text] [Related]
20. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
